2006. A paper appeared in Nature about Alzheimer’s disease.
The first author was Sylvain Lesne. A postdoc in a respected lab at the University of Minnesota.
It reported the thing the field had been waiting twenty years for. A specific toxic form of amyloid protein. Amyloid beta star 56.
Put it into young animals and their memory failed. Cause and effect, at last.
This mattered enormously. It gave every researcher in the field a precise target to aim at.
The paper was cited around 2,300 times. Between 2006 and 2022 it was the fourth most cited laboratory paper in the whole field.
Grants followed it. Careers followed it. Companies followed it.
One thing was odd from the start. Almost no other laboratory on earth ever managed to find amyloid beta star 56 themselves.
Nobody stopped.
August 2021. Matthew Schrag is a neurologist and physician at Vanderbilt.
A lawyer hired him to examine the science behind a small company’s Alzheimer’s drug. Cassava Sciences. The lawyer worked for short sellers, investors who profit when a share price falls. The fee was 18,000 dollars.
Hold that thought, because it matters later.
Schrag was teaching himself to read scientific images forensically. To know his method worked he needed practice on pictures somebody else had already flagged.
So he went to PubPeer. A public site where scientists post concerns about published papers. He searched for Alzheimer’s studies with the kind of images he was learning to read.
That search led him to the 2006 paper.
The images are western blots. Dark bands on a strip that show which proteins are in a sample and how much.
Separate experiments must produce different bands. That is the entire point of the technique.
Schrag ran the comparison. Bands that should have been independent matched at a correlation of 0.98.
He kept going. The same problems appeared across dozens of papers by the same author.
Here is what he did with a finding worth a fortune to the people paying him.
January 2022. He took it to the National Institutes of Health. He told the journals. He never shorted the stock.
21 July 2022. Science magazine published a six month investigation. Hundreds of images. More than 70 papers. Independent image analysts checked his work and agreed with him.
Then the money did something remarkable.
Months after Schrag first went to the NIH, that same researcher was awarded a fresh federal grant of 765,000 dollars. The program officer on that grant had been a co-author on his earlier amyloid work.
June 2024. Nature retracted the 2006 paper.
The notice cited signs of excessive manipulation. Splicing. Duplication. The use of an eraser tool.
Every author agreed to the retraction except the first author.
It is the second most cited paper ever retracted in the history of science.
He resigned from the University of Minnesota in 2025.
And it does not stop there. A separate investigation found apparent problems across 132 papers published between 1997 and 2023. The author was the director of the neuroscience division at the National Institute on Aging. The arm of the NIH that funds American Alzheimer’s research.
Now the honest part, and Schrag insisted on it himself.
This does not mean Alzheimer’s research is fake. Amyloid beta star 56 was one molecule. The broader amyloid theory rests on decades of other evidence.
What was lost was time, money and direction.
In 2023 alone the NIH spent about 1.6 billion dollars on projects mentioning amyloid. Around half its entire Alzheimer’s budget.
Think about the arithmetic. One paper. 2,300 citations. Sixteen years.
Sixteen years is a diagnosis, a decline and a funeral. Somebody in your family has already lived through that window. Every one of those years, the field was partly aimed at a molecule almost nobody else could find.
Another image analyst said the quiet part. It sent studies in the wrong direction. It created false hope in families.
A man taking a small side job, calibrating a tool on somebody else’s flagged pictures, walked into the biggest problem in his field by accident. Then reported it to a federal agency instead of the people paying him.
Schrag said one line about all of it.
You can’t cheat to cure a disease. Biology doesn’t care.
